Tyra Biosciences (TYRA) Cash from Investing Activities (2020 - 2026)

Tyra Biosciences' Cash from Investing Activities history runs 7 years deep, the most recent figure standing at -$120.2 million for Q1 2026.

• Quarterly Cash from Investing Activities fell 475.46% year-over-year to -$120.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$79.8 million (up 5.5% YoY) and the FY2025 annual result came in at $72.5 million, up 173.64% from the prior year.
• Cash from Investing Activities was -$120.2 million for Q1 2026 at Tyra Biosciences, down from $34.4 million in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $34.4 million in Q4 2025 and bottomed at -$145.0 million in Q2 2024.
• A 5-year average of -$17.1 million and a median of -$43000.0 in 2023 frame the typical range for Cash from Investing Activities.
• Annual changes were most pronounced in 2023 — Cash from Investing Activities slumped 687700.0% — and 2024, when it surged 44180.49%.
• Tyra Biosciences' Cash from Investing Activities stood at -$21000.0 in 2022, then slumped by 687700.0% to -$144.4 million in 2023, then soared by 104.82% to $7.0 million in 2024, then jumped by 394.06% to $34.4 million in 2025, then tumbled by 449.78% to -$120.2 million in 2026.
• Business Quant data shows TYRA's Cash from Investing Activities at -$120.2 million in Q1 2026, $34.4 million in Q4 2025, and -$14.8 million in Q3 2025.